drugset
drugset / Trial / NCT04697511

Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy Participants

NCT04697511 ↗

Phase 1 Completed 16 enrolled Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
NaSequentialOpen-labelOther

Summary

The study will investigate the effect of single dose and multiple doses of M2951 on midazolam Pharmacokinetics (PK) in healthy participants.

Timeline

Start
2021-01-11
Primary completion
2021-02-25
Completion
2021-02-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Evobrutinib Small molecule — Oral
Subject Midazolam Small molecule — Oral

Indications

No indication recorded.